Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of FGF21 that is designed to regulate key metabolic pathways to decrease liver fat, ...

The researchers randomly assigned 84 participants with biopsy-confirmed F2/F3 MASH to receive once-monthly injections of 300 mg efimosfermin alpha (43 patients) or placebo (41 patients) for 24 weeks.

Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed.

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

Efimosfermin, formerly known as BOS-580, was originally developed by Novartis. Boston Pharma licensed global rights to the asset in 2020; financial terms were not disclosed. Beyond GSK’s upfront ...

Improvements in collagen formation and degradation biomarkers indicate that efimosfermin reduces fibrotic activity, consistent with histopathology findings in participants with F2 and F3 MASH after 24 ...

Together, we look forward to efimosfermin’s ongoing journey to become a best-in-class treatment for patients with SLD.” The addition of efimosfermin further strengthens GSK’s hepatology pipeline of ...

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic live. CAMBRIDGE, Mass., May 14, ...

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD).